A Novel Therapy System for the Treatment of Occult Prostate Cancer
Annual rept. 1 Apr 2005-31 Mar 2006
CINCINNATI UNIV OH
Pagination or Media Count:
The goal of this research was to investigate efficacy and mechanisms of H5BVIFN- , a novel immunotherapeutic agent, against prostate cancer in animal models. The objectives in year 2 were to determine efficacy of a mixture of irradiated TRAMP-L5 mouse prostate cancer cells and lyophilized H5BVIFN- in regressing orthotopic tumors of TRAMP-L5 cells and to study effects of intratumoral injection of H5BVIFN- on expression of immune stimulatory cytokine in tumors. We found that subcutaneous injections of irradiated TRAMP-L5 cells, recombinant IFN- , or H5BVIFN- , partially inhibited orthotopic growth of TRAMP-L5 cells in syngeneic mice. An additive inhibitory effect was observed in mice injected with a mixture of irradiated TRAMP-L5 cells and H5BVIFN- . However, none of the therapies was able to eradicate orthotopic tumors. Intratumoral delivery of H5BVIFN- was not able to enhance expression of immunestimulatory cytokines interleukin IL-2, IL-12, or interferon-Y.
- Medicine and Medical Research